What's Happening?
Latham & Watkins LLP represented Blackstone Life Sciences in a significant R&D funding agreement. Funds managed by Blackstone Life Sciences will provide US$750 million to Johnson & Johnson. This funding is designated to support the Phase 3 clinical development
of OLN324, an investigational therapy aimed at serious retinal vascular diseases. The agreement, which is reported to be the largest R&D funding agreement in 2026, will specifically finance the Phase 3 clinical program for conditions such as wet age-related macular degeneration and diabetic macular edema. This development follows the anticipated acquisition of Ollin Biosciences, Inc. The legal team from Latham & Watkins involved in this transaction included Bay Area partners Todd Trattner and Haim Zaltzman, with associates William Lane and William Jackson handling healthcare finance. Tax matters were advised by Los Angeles partner Eric Cho and associate Sam Yang, while intellectual property advice came from New York partner Rachel Blitzer and Washington, D.C. partner Reba Rabenstein, with associate Drew Roberts. Healthcare regulatory matters were handled by Washington, D.C. counsel Chad Jennings.
Why It's Important?
This US$750 million R&D funding agreement is significant for the pharmaceutical and life sciences sectors, highlighting a growing trend of substantial private investment in late-stage drug development. For Blackstone Life Sciences, this represents a strategic investment in a potentially high-impact therapeutic area, diversifying its portfolio and reinforcing its position in the healthcare market. For Johnson & Johnson, the funding provides crucial capital to advance OLN324 through its final clinical trial phase, potentially accelerating the availability of a new treatment for debilitating retinal vascular diseases. The success of OLN324 could offer new hope for patients suffering from conditions like wet age-related macular degeneration and diabetic macular edema, which are leading causes of vision loss. This collaboration also underscores the increasing complexity of healthcare financing, where specialized legal expertise, as provided by Latham & Watkins, is essential to navigate intricate agreements involving intellectual property, regulatory compliance, and tax implications.
What's Next?
The immediate next step involves the expected closing of the acquisition of Ollin Biosciences, Inc., which will pave the way for the full implementation of the funding agreement. Following this, Johnson & Johnson will proceed with the Phase 3 clinical trials for OLN324, focusing on its efficacy and safety for wet age-related macular degeneration and diabetic macular edema. The outcome of these trials will be critical in determining the future regulatory approval and market launch of the investigational therapy. Success in Phase 3 could lead to a new treatment option for millions of patients and a significant return on investment for Blackstone Life Sciences. Conversely, any setbacks could impact both companies' financial outlooks and strategic plans in the ophthalmology market. The legal and financial structures established by Latham & Watkins will continue to govern the partnership and funding disbursements throughout the development process.
Beyond the Headlines
This funding agreement reflects a broader shift in pharmaceutical R&D financing, where large private equity firms like Blackstone are playing an increasingly central role in de-risking and accelerating drug development. By providing substantial capital for late-stage trials, these firms enable pharmaceutical companies to focus on their core research while sharing the financial burden and potential rewards. This model could lead to more efficient drug development pathways, but it also raises questions about the influence of private capital on research priorities and drug pricing. The focus on retinal vascular diseases highlights the ongoing need for innovative treatments in ophthalmology, a field with significant unmet medical needs due to an aging global population. The legal intricacies of such large-scale, cross-corporate collaborations, as managed by Latham & Watkins, also set precedents for future partnerships in the life sciences sector, emphasizing the importance of robust legal frameworks in complex scientific and financial ventures.













